04 February 2019 by Bahri Akdeniz

Investigation of frailty status in patients with pulmonary hypertension


Frailty is a clinical syndrome which can cause to reduced physiological reserve. Frailty is characterized by reduced strength and cognitive function, loss of endurance, loss of mobility, slowing, and relative inactivity. It has been shown that there was an accelerated rate of decline into a frail state in patients with chronic diseases but the relationship between chronic lung disease and frailty is not yet understood in patients with Pulmonary Hypertension (PH).


To investigate the frailty status in patients with PH.


Thirty-six patients with stable PH participated in this study. Frailty was defined by Fried Frailty Index. It includes five domains: unintentional weight loss, exhaustion, weakness, slow walking speed, and low physical activity. More than 3 frailty criteria was accepted as frail and one or two criteria was accepted to pre-frail patient.
Results: Overall, 16.7% (n=6) of the patients had frailty and 77.7% (n=28) of the patients was defined as pre-frail according to the Fried phenotype model, whilst only 5.6% of the patients (n=2) did not meet any of the frailty criteria. Of all the criterion, reduced activity was met the most (88.9%), followed by exhaustion, weakness, slowness, weight loss.


This high pre-frail and frail rates provides a potential basis for clinical assessment for those are frail or at risk. Methods for increasing physical activity should be in treatments for patients with PH.


Key Contributors

Buse Ozcan Kahraman 1, Bahri Akdeniz 2, Ismail Ozsoy 3, Ebru Ozpelit 2, Bihter Senturk, Serap Acar 1, Can Sevinc 4, Sema Savcı 1 1 School of Physical Therapy and Rehabilitation, Dokuz Eylul University, Izmir, Turkey 2 Department of Cardiology, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey 3 School of Physical Therapy and Rehabilitation, Kırsehir Ahi Evran University, Kırsehir, Turkey 4 Department of Chest Disease, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey

Comments (0)

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI